a heart shaped object with a pink and blue swirl

The first-of-its-kind AI-driven, non-blood-contact smart closed-loop diagnostic and treatment platform for heart conditions

Integrating physiological sensing, biomechanical support, and molecularly targeted intervention into a single implantable platform redefines the diagnosis, monitoring, and treatment of heart failure and structural heart disease

Hydraulic Tech

Hollow tubes filled with tailored liquids

Customised Design

Gentle pressure can massage the ventricles

Advanced Cardio Care

Naturally conforms to the surface of the heart, providing effective support

Our Story: From concept to platform with three-decade pursuit

Cambridge CardioMatrix Ltd founded in Cambridge, UK, is a medical technology company dedicated to research and development. The establishment of our company aims to commercialize Dr. Zhou Xiaohui's groundbreaking cardiac innovations. Dr. Zhou's work spans biomechanics, soft robotics, cardiology and biomedical engineering.

Our journey began with a simple yet profound question: Can we create a biomechanical interface that enables the heart to repair itself? With this question in mind, Dr Zhou started from the hand-woven prototype in the 1990s and, after three decades of unremitting pursuit, has gradually progressed to the current light-curing, 3D-printed smart platform. This continuous research and development process eventually has led to the creation of ASD technology and built a strong intellectual property portfolio including patents in China and the United States.

Minimally Invasive, Smart, Closed-loop Cardiac Monitoring, Diagnostic and Support Platforms

Advanced cardiac support solutions tailored to individual patient needs

Our mission is to create minimally invasive, smartt, closed-loop cardiac monitoring, diagnostic and support platforms to help address the rising global burden of cardiovascular disease.

Global Medical Need: The Cardiovascular Disease Crisis

  • 523 million people worldwide are affected by cardiovascular diseases (CVDs)

  • 20 million deaths occur annually — one-third of all global deaths

  • China: 290 million CVD patients while heart attacks and heart failure cases continue to rise

  • UK: 7.6 million CVD patients with 175,000 annual deaths

Despite progress made in stents, pharmaceuticals and ventricular assist devices (VADs), the current therapies still fail to effectively address the mechanical functional decline of failing hearts.

CardioMatrix offers a new bio-mechanical integrated solution to this unmet medical need.